Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement

Area of Science:

• Cardiovascular Medicine
• Neurology
• Medical Devices

Background:

• Transcatheter aortic-valve replacement (TAVR) for aortic stenosis carries a risk of debris embolization.
• Cerebral embolic protection (CEP) devices aim to mitigate stroke risk during TAVR by capturing embolic debris.

Purpose of the Study:

• To evaluate the efficacy of cerebral embolic protection (CEP) devices in reducing periprocedural stroke in patients undergoing transfemoral TAVR.
• To assess the safety and impact of CEP on other adverse events, including disabling stroke, death, and acute kidney injury.

Main Methods:

• A randomized controlled trial involving 3000 patients with aortic stenosis undergoing transfemoral TAVR.
• Patients were assigned 1:1 to undergo TAVR with CEP or without CEP (control group).
• The primary endpoint was stroke occurring within 72 hours post-TAVR or before discharge.

Main Results:

• The incidence of stroke within 72 hours did not differ significantly between the CEP group (2.3%) and the control group (2.9%) (P=0.30).
• Disabling stroke occurred less frequently in the CEP group (0.5%) compared to the control group (1.3%).
• No substantial differences were observed in mortality, transient ischemic attacks, delirium, or acute kidney injury between the groups.

Conclusions:

• Cerebral embolic protection (CEP) did not significantly reduce the incidence of periprocedural stroke in patients undergoing transfemoral TAVR.
• The study's confidence intervals suggest that a potential benefit of CEP in reducing stroke during TAVR cannot be entirely excluded.
• Further research may be warranted to fully elucidate the role of CEP in TAVR procedures.